Is angiogenesis still an attractive target in metastatic castration-resistant prostate cancer?

BJU Int. 2015 Oct;116(4):500-1. doi: 10.1111/bju.13070.

Authors

André P Fay^{1

2}, Joaquim Bellmunt^{1

3}

Affiliations

¹ Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
² Faculdade de Medicina, Pontifícia Universidade Católica do Rio Grande do Sul, Porto Alegre, Brazil.
³ University Hospital del Mar, IMIM, Barcelona, Spain.

PMID: 26350576
DOI: 10.1111/bju.13070

No abstract available

Publication types

Editorial
Comment

MeSH terms

Antibodies, Monoclonal*
Antineoplastic Agents*
Humans
Male
Prostatic Neoplasms, Castration-Resistant / drug therapy*

Substances

Antibodies, Monoclonal
Antineoplastic Agents